Applications of privacy-enhancing technology to data sharing at a global pharmaceutical company

Click the button below to download the full text of the article.

Abstract: Janssen has been at the forefront of the recent pharmaceutical industry trend towards more transparency and sharing of clinical trials data, committing early on to make its data available for both internal and external innovation. Janssen is also committed to protecting patient privacy and giving individuals a voice on how their data is used and disclosed. This paper outlines Janssen’s data-sharing initiatives and describes how it is using leading-edge privacy-enhancing technologies (PETs) to mitigate privacy risks and find the right balance between innovation and privacy.

Keywords: privacy-enhancing technologies, data sharing, transparency, pharmaceutical industry, open data, clinical trial data

Stephen Bamford is the Head of Clinical Data Standards & Transparency at the Janssen Pharmaceutical Companies of Johnson & Johnson. Stephen has been a member of the Janssen team since 2016 and has helped to implement and support a number of data-sharing initiatives during this time. He has over 25 years of experience in management of clinical trials and research data with pharmaceutical, life science and research organisations. In 2004, Stephen founded the PHUSE organisation. Since inception, he has driven, and continues to drive, PHUSE, which now has over 10,000 global members. PHUSE runs over 25 well-attended events globally each year, including a data innovation symposium in partnership with the Food and Drug Administration.